Cited by 277Blood Pressure and Hypertension StudiesRenin-Angiotensin System StudiesHormonal Regulation and Hypertension

The DOI matches its Crossref record; 212 of the 213 references it cites were found in a registry or an index.

New Approaches in the Treatment of Hypertension

Oparil, Suzanne, Schmieder, Roland E.·2015·Circulation Research

Open this paper in CoChat — free account

Abstract

Hypertension is the most common modifiable risk factor for cardiovascular disease and death, and lowering blood pressure with antihypertensive drugs reduces target organ damage and prevents cardiovascular disease outcomes. Despite a plethora of available treatment options, a substantial portion of the hypertensive population has uncontrolled blood pressure. The unmet need of controlling blood pressure in this population may be addressed, in part, by developing new drugs and devices/procedures to treat hypertension and its comorbidities. In this Compendium Review, we discuss new drugs and interventional treatments that are undergoing preclinical or clinical testing for hypertension treatment. New drug classes, eg, inhibitors of vasopeptidases, aldosterone synthase and soluble epoxide hydrolase, agonists of natriuretic peptide A and vasoactive intestinal peptide receptor 2, and a novel mineralocorticoid receptor antagonist are in phase II/III of development, while inhibitors of aminopeptidase A, dopamine β-hydroxylase, and the intestinal Na(+)/H(+) exchanger 3, agonists of components of the angiotensin-converting enzyme 2/angiotensin(1-7)/Mas receptor axis and vaccines directed toward angiotensin II and its type 1 receptor are in phase I or preclinical development. The two main interventional approaches, transcatheter renal denervation and baroreflex activation therapy, are used in clinical practice for severe treatment resistant hypertension in some countries. Renal denervation is also being evaluated for treatment of various comorbidities, eg, chronic heart failure, cardiac arrhythmias and chronic renal failure. Novel interventional approaches in early development include carotid body ablation and arteriovenous fistula placement. Importantly, none of these novel drug or device treatments has been shown to prevent cardiovascular disease outcomes or death in hypertensive patients.

Integrity signals

Registry

Crossref · 10.1161/circresaha.116.303603

Cites

212 of 212 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Endarterectomy for Asymptomatic Carotid Artery Stenosis
WALKER, M. D. (1995) · JAMA · doi:10.1001/jama.1995.03520420037035 · Cited by 4,435
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
(2010) · The Lancet · doi:10.1016/s0140-6736(10)62039-9 · Cited by 2,242
Resistant Hypertension: Diagnosis, Evaluation, and Treatment
Calhoun, D. A., Jones, D. W., Textor, S. C., Goff, D. C., Murphy, T. P., Toto, R. D., White, A. J., Cushman, W. C., White, W. B., Sica, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.189141 · Cited by 2,240
A Controlled Trial of Renal Denervation for Resistant Hypertension
Bhatt, D. L., Kandzari, D. E., O'Neill, W. W., D'Agostino, R., Flack, J. M., Katzen, B. T., Leon, M. B., Liu, M., Mauri, L., Negoita, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402670 · Cited by 2,186
Self-citation
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
The North American Symptomatic Carotid Endarterectomy Trial
Ferguson, G. G., Eliasziw, M., Barr, H. W. K., Clagett, G. P., Barnes, R. W., Wallace, M. C., Taylor, D. W., Haynes, R. B., Finan, J. W., Hachinski, V., et al. (1999) · Stroke · doi:10.1161/01.str.30.9.1751 · Cited by 1,498
Neural control of renal function
DiBona, G. F., & Kopp, U. C. (1997) · Physiological Reviews · doi:10.1152/physrev.1997.77.1.75 · Cited by 1,212
Revascularization versus Medical Therapy for Renal-Artery Stenosis
The ASTRAL Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905368 · Cited by 1,194
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
Solomon, S. D., Zile, M. R., Pieske, B. M., Voors, A. A., Shah, A. M., Kraigher‐Krainer, E., Shi, V. C., Bransford, T. L., Takeuchi, M., Gong, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61227-6 · Cited by 1,171
Neural Control of Renal Function*
Kopp, U. C., & DiBona, G. F. (2020) · Reflex Control of the Circulation · doi:10.1201/9780367813338-17 · Cited by 1,126
Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis
Cooper, C. J., Murphy, T. P., Cutlip, D. E., Jamerson, K., Henrich, W. L., Reid, D., Cohen, D. J., Matsumoto, A. H., Steffes, M. W., Jaff, M. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310753 · Cited by 1,019
Clinical Practice Guidelines for the Management of Hypertension in the Community: A Statement by the American Society of Hypertension and the International Society of Hypertension
Weber, M. A., Schiffrin, E. L., White, W. B., Mann, S., Lindholm, L. H., Kenerson, J. G., Flack, J. M., Carter, B. L., Materson, B. J., Ram, C. V. S., et al. (2014) · The Journal of Clinical Hypertension · doi:10.1111/jch.12237 · Cited by 986
Use of Doppler Ultrasonography to Predict the Outcome of Therapy for Renal-Artery Stenosis
Radermacher, J., Chavan, A., Bleck, J. S., Vitzthum, A., Stoess, B., Gebel, M., Galanski, M., Koch, K. M., & Haller, H. G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102083440603 · Cited by 763
Prevalence of Resistant Hypertension in the United States, 2003–2008
Persell, S. D. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.170308 · Cited by 761
Stent Placement in Patients With Atherosclerotic Renal Artery Stenosis and Impaired Renal Function
Bax, L., Woittiez, A.-J. J., Kouwenberg, H. J., Mali, W. P. T. M., Buskens, E., Beek, F. J. A., Braam, B. G., Huysmans, F. T. M., Kool, L. J. S., Rutten, M. J. C. M., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-12-200906160-00119 · Cited by 699
Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover.
Esler, M., Jennings, G., Korner, P., Willett, I., Dudley, F., Hasking, G., Anderson, W., & Lambert, G. (1988) · Hypertension · doi:10.1161/01.hyp.11.1.3 · Cited by 642
Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension
Chapman, N., Dobson, J., Wilson, S. L., Dahlöf, B., Sever, P., Wedel, H., & Poulter, N. R. (2007) · Hypertension · doi:10.1161/01.hyp.0000259805.18468.8c · Cited by 630
Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study
Krum, H., Schlaich, M. P., Sobotka, P. A., Böhm, M., Mahfoud, F., Rocha‐Singh, K. J., Katholi, R. E., & Esler, M. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62192-3 · Cited by 622
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases
Imig, J. D., & Hammock, B. D. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2875 · Cited by 616
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Pitt, B., Køber, L., Ponikowski, P. P., Gheorghiade, M., Filippatos, G. S., Krum, H., Nowack, C., Kolkhof, P., Kim, S. Y., & Zannad, F. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht187 · Cited by 610
Baroreflex Activation Therapy Lowers Blood Pressure in Patients With Resistant Hypertension
Bisognano, J. D., Bakris, G., Nadim, M. K., Sanchez, L., Kroon, A. A., Schafer, J., de Leeuw, P. W., & Sica, D. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.008 · Cited by 600
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
Ruilope, L. M., Dukát, A., Böhm, M., Lacourcière, Y., Gong, J., & Lefkowitz, M. P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61966-8 · Cited by 598
Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial
Kostis, J. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2003.09.014 · Cited by 579
Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension
Mahfoud, F., Schlaich, M. P., Kindermann, I., Ukena, C., Cremers, B., Brandt, M. C., Hoppe, U. C., Vonend, O., Rump, L. C., Sobotka, P. A., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.991869 · Cited by 577
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial
Kandzari, D. E., Bhatt, D. L., Brar, S. K., Devireddy, C. M., Esler, M., Fahy, M. P., Flack, J. M., Katzen, B. T., Lea, J. P., Lee, D. P., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu441 · Cited by 552
Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial
Azizi, M., Sapoval, M., Gosse, P., Monge, M., Bobrie, G., Delsart, P., Midulla, M., Mounier-Véhier, C., Courand, P.-Y., Lantelme, P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61942-5 · Cited by 519
Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)
Gu, J., Noè, A., Chandra, P., Al‐Fayoumi, S., Ligueros‐Saylan, M., Sarangapani, R., Maahs, S., Ksander, G. M., Rigel, D. F., Jeng, A. Y., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009343932 · Cited by 505
Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension
Brandt, M. C., Mahfoud, F., Reda, S., Schirmer, S. H., Erdmann, E., Böhm, M., & Hoppe, U. C. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.034 · Cited by 501
Efficacy of low-dose spironolactone in subjects with resistant hypertension
Nishizaka, M. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)01032-x · Cited by 500
EPOXIDE HYDROLASES: Mechanisms, Inhibitor Designs, and Biological Roles
Morisseau, C. H. P., & Hammock, B. D. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095920 · Cited by 482
Resistant hypertension? Assessment of adherence by toxicological urine analysis
Jung, O., Gechter, J. L., Wunder, C., Paulke, A., Bartel, C., Geiger, H., & Toennes, S. W. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835e2286 · Cited by 474
Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF)
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K. B., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft052 · Cited by 466
Validation of a Brachial Cuff-Based Method for Estimating Central Systolic Blood Pressure
Weber, T., Wassertheurer, S., Rammer, M., Maurer, E., Hametner, B., Mayer, C. C., Kropf, J., & Eber, B. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.176313 · Cited by 462
Discovery and Characterization of Alamandine
Lautner, R. Q., Villela, D. C., Fraga-Silva, R. A., Silva, N., Verano‐Braga, T., Costa-Fraga, F. P., Jankowski, J., Jankowski, V., Sousa, F. B. D., Alzamora, A. C., et al. (2013) · Circulation Research · doi:10.1161/circresaha.113.301077 · Cited by 440
Carotid Baroreceptor Stimulation, Sympathetic Activity, Baroreflex Function, and Blood Pressure in Hypertensive Patients
Heusser, K., Tank, J., Engeli, S., Diedrich, A., Menne, J., Eckert, S., Peters, T., Sweep, F. C. G. J., Haller, H., Pichlmaier, A. M., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.140665 · Cited by 433
Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
Kolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Bärfacker, L., Eitner, F., Albrecht-Küpper, B., & Schäfer, S. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000091 · Cited by 430
Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., Liu, F., Zhang, K., & Zhang, C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.59 · Cited by 427
High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis
Tomaszewski, M., White, C., Patel, P., Masca, N., Damani, R., Hepworth, J., Samani, N. J., Gupta, P., Madira, W., Stanley, A., et al. (2014) · Heart · doi:10.1136/heartjnl-2013-305063 · Cited by 404
Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects
Haschke, M., Schuster, M., Poglitsch, M., Loibner, H., Salzberg, M. O., Bruggisser, M., Penninger, J. M., & Krähenbühl, S. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0072-7 · Cited by 362
Renal Denervation in Moderate to Severe CKD
Hering, D., Mahfoud, F., Walton, A. S., Krum, H., Lambert, G. W., Lambert, E. A., Sobotka, P. A., Böhm, M., Cremers, B., Esler, M. D., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011111062 · Cited by 361
Novel Baroreflex Activation Therapy in Resistant Hypertension
Scheffers, I. J. M., Kroon, A. A., Schmidli, J., Jordan, J., Tordoir, J. H. M., Mohaupt, M. G., Luft, F. C., Haller, H. G., Menne, J., Engeli, S., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.089 · Cited by 356
Angiotensin Synthesis in the Brain and Increased Turnover in Hypertensive Rats
Ganten, D., Hermann, K., Bayer, C., Unger, T., & Lang, R. E. (1983) · Science · doi:10.1126/science.6879184 · Cited by 323
Effects of Aldosterone on the Vasculature
Schiffrin, E. L. (2006) · Hypertension · doi:10.1161/01.hyp.0000201443.63240.a7 · Cited by 302
Human Recombinant ACE2 Reduces the Progression of Diabetic Nephropathy
Oudit, G. Y., Liu, G. C., Zhong, J., Basu, R., Chow, F. L., Zhou, J., Loibner, H., Janzek, E., Schuster, M., Penninger, J. M., et al. (2009) · Diabetes · doi:10.2337/db09-1218 · Cited by 298
Vasopeptidase Inhibitors
Corti, R., Burnett, J. C. J., Rouleau, J. L., Ruschitzka, F. T., & Lüscher, T. F. (2001) · Circulation · doi:10.1161/hc4001.097191 · Cited by 294
Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial
Hoppe, U. C., Brandt, M. C., Wachter, R., Beige, J., Rump, L. C., Kroon, A. A., Cates, A. W., Lovett, E. G., & Haller, H. G. (2012) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2012.04.004 · Cited by 292
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study
Tissot, A. C., Maurer, P., Nussberger, J., Sabat, R., Pfister, T., Ignatenko, S., Volk, H., STOCKER, H., Müller, P., Jennings, G. T., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60381-5 · Cited by 287
Prolonged Activation of the Baroreflex Produces Sustained Hypotension
Lohmeier, T. E., Irwin, E. D., Rossing, M. A., Serdar, D. J., & Kieval, R. S. (2004) · Hypertension · doi:10.1161/01.hyp.0000111837.73693.9b · Cited by 283
Vasoactive intestinal peptide: cardiovascular effects
Henning, R. J. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00229-7 · Cited by 280
Discovery of BAY 94‐8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
Bärfacker, L., Kühl, A., Hillisch, A., Grosser, R., Figueroa‐Pérez, S., Heckroth, H., Nitsche, A., Ergüden, J., Gielen‐Haertwig, H., Schlemmer, K., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200081 · Cited by 276
Assessment of Renal Artery Stenosis Severity by Pressure Gradient Measurements
Bruyne, B. D., Manoharan, G., Pijls, N. H. J., Verhamme, K. M. C., Maďarič, J., Bartúnek, J., Vanderheyden, M., & Heyndrickx, G. R. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.074 · Cited by 275
Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial
Esler, M., Böhm, M., Sievert, H., Rump, C., Schmieder, R. E., Krum, H., Mahfoud, F., & Schlaich, M. P. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu209 · Cited by 265
Efficacy of Revascularization For Renal Artery Stenosis Caused by Fibromuscular Dysplasia
Trinquart, L., Mounier‐Véhier, C., Sapoval, M. R., Gagnon, N., & Plouin, P. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.152918 · Cited by 262
Antiandrogenic Effect of Spirolactones: Mechanism of Action
Corvol, P. L., Michaud, A., Ménard, J., FREIFELD, M., & MAHOUDEAU, J. A. (1975) · Endocrinology · doi:10.1210/endo-97-1-52 · Cited by 259
Renal Resistance Index and Progression of Renal Disease
Radermacher, J., Ellis, S., & Haller, H. G. (2002) · Hypertension · doi:10.1161/hy0202.103782 · Cited by 259
Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension
Mahfoud, F., Ukena, C., Schmieder, R. E., Cremers, B., Rump, L. C., Vonend, O., Weil, J., Schmidt, M. U., Hoppe, U. C., Zeller, T., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000949 · Cited by 250
Baroreflex Activation Therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial
Bakris, G. L., Nadim, M. K., Haller, H. G., Lovett, E. G., Schafer, J. E., & Bisognano, J. D. (2012) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2012.01.003 · Cited by 246
Role of steroid 11 beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans.
Kawamoto, T., Mitsuuchi, Y., Toda, K., Yokoyama, Y., Miyahara, K., Miura, S., Ohnishi, T., Ichikawa, Y., Nakao, K., & Imura, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.4.1458 · Cited by 245
Evidence for Angiotensin-converting Enzyme 2 as a Therapeutic Target for the Prevention of Pulmonary Hypertension
Ferreira, A. J., Shenoy, V., Yamazato, Y., Sriramula, S., Francis, J., Yuan, L., Castellano, R. K., Ostrov, D. A., Oh, S. P., Katovich, M. J., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200811-1678oc · Cited by 244
Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors
Xu, D., Li, N., He, Y., Timofeyev, V., Lü, L., Tsai, H.-J., Kim, I.-H., Tuteja, D., Mateo, R. K. P., Singapuri, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609158103 · Cited by 235
Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension
Kario, K., Sun, N., Chiang, F., Supasyndh, O., Baek, S. H., Inubushi-Molessa, A., Zhang, Y., Gotou, H., Lefkowitz, M. P., & Zhang, J. Y. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.02002 · Cited by 232
Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial
Calhoun, D. A., White, W. B., Krum, H., Guo, W., Bermann, G., Trapani, A., Lefkowitz, M. P., & Ménard, J. (2011) · Circulation · doi:10.1161/circulationaha.111.029892 · Cited by 227
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity
Ambühl, P. M., Tissot, A. C., Fulurija, A., Maurer, P., Nussberger, J., Sabat, R., Nief, V., Schellekens, C., Sladko, K., Roubicek, K., et al. (2006) · Journal of Hypertension · doi:10.1097/hjh.0b013e32800ff5d6 · Cited by 220
Functional role of renal afferents.
Stella, A., & Zanchetti, A. (1991) · Physiological Reviews · doi:10.1152/physrev.1991.71.3.659 · Cited by 216
Aldosterone Synthase Inhibition With LCI699
Amar, L., Azizi, M., Ménard, J., Peyrard, S., Watson, C. E., & Plouin, P. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.157271 · Cited by 208
Characteristics of Resistant Hypertension in a Large, Ethnically Diverse Hypertension Population of an Integrated Health System
Sim, J. J., Bhandari, S. K., Shi, J., Liu, I. L. A., Calhoun, D. A., McGlynn, E. A., Kalantar-Zadeh, K., & Jacobsen, S. J. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.06.017 · Cited by 206
Randomized Comparison of Renal Denervation Versus Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension
Rosa, J., Widimský, P., Toušek, P., Petrák, O., Čurila, K., Waldauf, P., Bednář, F., Zelinka, T., Holaj, R., Štrauch, B., et al. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.04019 · Cited by 198
Renal nerves in the pathogenesis of hypertension in experimental animals and humans
Katholi, R. E. (1983) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1983.245.1.f1 · Cited by 197
Mass-Spectrometric Identification of a Novel Angiotensin Peptide in Human Plasma
Jankowski, V., Vanholder, R. C., van der Giet, M., Tölle, M., Karadogan, S., Gobom, J., Furkert, J., Oksche, A., Krause, E., Tran, T. N. A., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000253889.09765.5f · Cited by 197
A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule
Fagart, J., Hillisch, A., Huyet, J., Bärfacker, L., Fay, M., Pleiß, U., Pook, E., Schäfer, S., Rafestin-Oblin, M. E., & Kolkhof, P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.131342 · Cited by 196
European consensus on the diagnosis and management of fibromuscular dysplasia
Persu, A., Giavarini, A., Touzé, E., Januszewicz, A., Sapoval, M. R., Azizi, M., Barral, X., Jeunemaı̂tre, X., Morganti, A., Plouin, P., et al. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000213 · Cited by 196
The evolution of aldosterone antagonists
Garthwaite, S. M., & McMahon, E. G. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.10.005 · Cited by 192
Refractory Hypertension
Calhoun, D. A., Booth, J. N., Oparil, S., Irvin, M. R., Shimbo, D., Lackland, D. T., Howard, G., Safford, M. M., & Muntner, P. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.02026 · Cited by 186
Therapeutic Drug Monitoring Facilitates Blood Pressure Control in Resistant Hypertension
Brinker, S. K., Pandey, A., Ayers, C., Price, A. L., Raheja, P., Arbique, D., Das, S. R., Halm, E., Kaplan, N., & Vongpatanasin, W. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.067 · Cited by 181
Increased sensitivity of the arterial chemoreceptor drive in young men with mild hypertension
Trzebski, A., Tafil, M., Zółtowski, M., & Przybylski, J. (1982) · Cardiovascular Research · doi:10.1093/cvr/16.3.163 · Cited by 177
Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial
Lobo, M. D., Sobotka, P. A., Stanton, A. V., Cockcroft, J., Sulke, N., Dolan, E., van der Giet, M., Hoyer, J. D., FURNISS, S. S., Foran, J. P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62053-5 · Cited by 177
Candoxatril, a neutral endopeptidase inhibitor
Bevan, E. G., Connell, J., Doyle, J., Carmichael, H. A., Davies, D. L., Lorimer, A. R., & Mclnnes, G. T. (1992) · Journal of Hypertension · doi:10.1097/00004872-199207000-00002 · Cited by 173
Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy
Ceral, J., Habrdová, V., Voříšek, V., Bima, M., Pelouch, R., & Solař, M. (2010) · Hypertension Research · doi:10.1038/hr.2010.183 · Cited by 170
Catheter-Based Renal Nerve Ablation and Centrally Generated Sympathetic Activity in Difficult-to-Control Hypertensive Patients: Prospective Case Series
Brinkmann, J., Heusser, K., Schmidt, B. M., Menne, J., Klein, G., Bauersachs, J., Haller, H., Sweep, F. C., Diedrich, A., Jordan, J., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.201186 · Cited by 166
Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis
Štrauch, B., Petrák, O., Zelinka, T., Rosa, J., Krátká, Z., Indra, T., Chytil, L., Marešová, V., Kurcová, I., Holaj, R., et al. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283652c61 · Cited by 165
Multitarget Stool DNA Testing for Colorectal-Cancer Screening
Brenner, H., Werner, S., & Chen, H. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1405215 · Cited by 164
Intestinal Inhibition of the Na + /H + Exchanger 3 Prevents Cardiorenal Damage in Rats and Inhibits Na + Uptake in Humans
Spencer, A. G., Labonté, E. D., Rosenbaum, D. P., Plato, C. F., Carreras, C. W., Leadbetter, M. R., Kozuka, K., Kohler, J. N., Koo-McCoy, S., He, L., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007790 · Cited by 161
Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
Kolkhof, P., & Borden, S. A. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.025 · Cited by 158
Effects of Renal Sympathetic Denervation on Arterial Stiffness and Central Hemodynamics in Patients With Resistant Hypertension
Brandt, M. C., Reda, S., Mahfoud, F., Lenski, M., Böhm, M., & Hoppe, U. C. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.959 · Cited by 155
Angiotensin-(1-7) with Thioether Bridge: An Angiotensin-Converting Enzyme-Resistant, Potent Angiotensin-(1-7) Analog
Kluskens, L., Nelemans, S. A., Rink, R., de Vries, L., Meter-Arkema, A. H., Wang, Y., Walther, T., Kuipers, A., Moll, G. N., & Haas, M. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146431 · Cited by 150
Blood pressure changes after renal denervation at 10 European expert centers
Persu, A., Jin, Y., Azizi, M., Baelen, M., Völz, S., Elvan, A., Severino, F., Rosa, J., Adıyaman, A., Elmula, F. E. M. F., et al. (2013) · Journal of Human Hypertension · doi:10.1038/jhh.2013.88 · Cited by 150
Pharmacokinetics and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single‐ and Multiple‐Dose Studies in Healthy Human Subjects
Chen, D., Whitcomb, R., MacIntyre, E. D., Tran, V., Do, Z. N., Sabry, J. H., Patel, D. V., Anandan, S., Gless, R. D., & Webb, H. K. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010397049 · Cited by 149
Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II
Richards, M., Wittert, G., Crozier, I., Espiner, E. A., Yandle, T. G., Ikram, H., & Frampton, C. M. (1993) · Journal of Hypertension · doi:10.1097/00004872-199304000-00011 · Cited by 145
Renin–Angiotensin Blockade Combined With Natriuretic Peptide System Augmentation
von Lueder, T. G., Sangaralingham, S. J., Wang, B. H., Kompa, A. R., Atar, D., Burnett, J. C. J., & Krum, H. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000289 · Cited by 131
A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity
Dietz, J. D., Du, S., Bolten, C. W., Payne, M., Xia, C., Blinn, J. R., Funder, J. W., & Hu, X. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.103580 · Cited by 126
VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins
Couvineau, A., & Laburthe, M. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01676.x · Cited by 122
Prediction of Off-Target Effects on Angiotensin-Converting Enzyme 2
Kulemina, L. V., & Ostrov, D. A. (2011) · SLAS DISCOVERY · doi:10.1177/1087057111413919 · Cited by 122
Tonic activity of carotid body chemoreceptors contributes to the increased sympathetic drive in essential hypertension
Siński, M., Lewandowski, J., Przybylski, J., Bidiuk, J., Abramczyk, P., Ciarka, A., & Gaciong, Z. A. (2011) · Hypertension Research · doi:10.1038/hr.2011.209 · Cited by 121
Neurogenic Hypertension
Jannetta, P. J., Segal, R., Wolfson, S. K., Dujovny, M., SEMBA, A., & Cook, E. E. (1985) · Annals of Surgery · doi:10.1097/00000658-198508000-00018 · Cited by 119
Posterior fossa neurovascular anomalies in essential hypertension
Naraghi, R., Huk, W. J., Fahlbusch, R., Geiger, H., Crnac, J., Luft, F. C., & Engels, G. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90289-5 · Cited by 118
Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects
Brown, M. J., Coltart, J., Gunewardena, K. A., Ritter, J. M., Auton, T. R., & Glover, J. F. (2004) · Clinical Science · doi:10.1042/cs20030381 · Cited by 118
Prolonged Activation of the Baroreflex Abolishes Obesity-Induced Hypertension
Lohmeier, T. E., Dwyer, T. M., Irwin, E. D., Rossing, M. A., & Kieval, R. S. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.087874 · Cited by 118
Chemoreceptor Hypersensitivity, Sympathetic Excitation, and Overexpression of ASIC and TASK Channels Before the Onset of Hypertension in SHR
Tan, Z., Lu, Y., Whiteis, C. A., Simms, A. E., Paton, J. F. R., Chapleau, M. W., & Abboud, F. M. (2009) · Circulation Research · doi:10.1161/circresaha.109.206946 · Cited by 117
Surgical Removal of the Carotid Body for Bronchial Asthma
Nakayama, K. (1961) · Diseases of the Chest · doi:10.1378/chest.40.6.595 · Cited by 117
Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer
Rodgers, K. E., Oliver, J., & diZerega, G. S. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0078-4 · Cited by 115
Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt
Lea, W. B., Kwak, E. S., Luther, J. M., Fowler, S. M., Wang, Z., Ma, J., Fogo, A. B., & Brown, N. J. (2009) · Kidney International · doi:10.1038/ki.2009.9 · Cited by 115
Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases
Ferreira, A. J., Shenoy, V., Qi, Y., Fraga-Silva, R. A., Santos, R. A. S., Katovich, M. J., & Raizada, M. K. (2010) · Experimental Physiology · doi:10.1113/expphysiol.2010.055277 · Cited by 112
Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension
Colussi, G., Catena, C., & Sechi, L. A. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283599b6a · Cited by 112
Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets
Treml, B., Neu, N., Kleinsasser, A. T., Gritsch, C., Finsterwalder, T., Geiger, R., Schuster, M., Janzek, E., Loibner, H., Penninger, J. M., et al. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181c03009 · Cited by 107
Study of Aldosterone Synthase Inhibition as an Add‐On Therapy in Resistant Hypertension
Karns, A. D., Bral, J. M., Hartman, D., Peppard, T., & Schumacher, C. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12051 · Cited by 104
Aldosterone synthase inhibition in humans
Azizi, M., Amar, L., & Ménard, J. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs388 · Cited by 104
Phase I and Pharmacokinetic Study of Angiotensin-(1-7), an Endogenous Antiangiogenic Hormone
Petty, W. J., Miller, A. A., McCoy, T. P., Gallagher, P. E., Tallant, E. A., & Torti, F. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1957 · Cited by 102
Decrease of blood pressure by ventrolateral medullary decompression in essential hypertension
Geiger, H., Naraghi, R., Schobel, H., Frank, H., Sterzel, R. B., & Fahlbusch, R. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11343-5 · Cited by 102
Angiotensin-(1–9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis
Ocaranza, M. P., Moya, J., Barrientos, V., Alzamora, R., Hevia, D., Morales, C., Pinto, M., Escudero, N., Garcı́a, L., Novoa, U., et al. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000094 · Cited by 100
Renal Denervation in Moderate Treatment-Resistant Hypertension
Ott, C., Mahfoud, F., Schmid, A., Ditting, T., Sobotka, P. A., Veelken, R. A., Spies, A., Ukena, C., Laufs, U., Uder, M., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.06.023 · Cited by 99
Wilder's principle: pre-treatment value determines post-treatment response
Messerli, F. H., Bangalore, S., & Schmieder, R. E. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu467 · Cited by 94
Rationale and Design of ARTS: A Randomized, Double-Blind Study of BAY 94-8862 in Patients with Chronic Heart Failure and Mild or Moderate Chronic Kidney Disease
Pitt, B., Filippatos, G. S., Gheorghiade, M., Køber, L., Krum, H., Ponikowski, P. P., Nowack, C., Kolkhof, P., Kim, S., & Zannad, F. M. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs061 · Cited by 92
The Renin-Angiotensin System
Oparil, S., & Haber, E. (1974) · New England Journal of Medicine · doi:10.1056/nejm197408292910905 · Cited by 91
Renal Denervation
Persu, A., Renkin, J. P., Thijs, L., & Staessen, J. A. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.195263 · Cited by 88
Antihypertensive and Laxative Effects by Pharmacological Inhibition of Sodium-Proton-Exchanger Subtype 3–Mediated Sodium Absorption in the Gut
Linz, D., WIRTH, K. J., Linz, W., Heuer, H., Frick, W., Hofmeister, A., Heinelt, U., Arndt, P., Schwahn, U., Böhm, M., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.201590 · Cited by 87
An Endogenous Ouabain-Like Factor Associated with Hypertensive Pregnant Women*
Graves, S. W., & Williams, G. H. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-6-1070 · Cited by 86
Improved Cardiac Structure and Function With Chronic Treatment Using an Implantable Device in Resistant Hypertension
Bisognano, J. D., Kaufman, C. L., Bach, D. S., Lovett, E. G., & de Leeuw, P. W. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.048 · Cited by 85
Independence of the Blood Pressure Lowering Effect and Efficacy of the Angiotensin Receptor Neprilysin Inhibitor, LCZ696, in Patients with Heart Failure with Preserved Ejection Fraction: An Analysis of the PARAMOUNT Trial
Jhund, P. S., Claggett, B. L., Packer, M., Zile, M. R., Voors, A. A., Pieske, B. M., Lefkowitz, M. P., Shi, V. C., Bransford, T. L., McMurray, J. J. V., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.76 · Cited by 83
New Cardiovascular and Pulmonary Therapeutic Strategies Based on the Angiotensin‐Converting Enzyme 2/Angiotensin‐(1–7)/Mas Receptor Axis
Ferreira, A. J., Murça, T. M., Fraga-Silva, R. A., Castro, C. H., Raizada, M. K., & Santos, R. A. S. (2012) · International Journal of Hypertension · doi:10.1155/2012/147825 · Cited by 82
PC18, a Specific Aminopeptidase N Inhibitor, Induces Vasopressin Release by Increasing the Half-Life of Brain Angiotensin III
Goazigo, A. R.-L., Mota, N. D., Zini, S., Cadel, S., Fournié‐Zaluski, M., Roques, B. P., Corvol, P. L., & Llorens‐Cortés, C. (1999) · Neuroendocrinology · doi:10.1159/000054439 · Cited by 82
A new strategy for treating hypertension by blocking the activity of the brain renin–angiotensin system with aminopeptidase A inhibitors
Gao, J., Marc, Y., Iturrioz, X., Leroux, V., Balavoine, F., & Llorens‐Cortés, C. (2014) · Clinical Science · doi:10.1042/cs20130396 · Cited by 81
Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients
Eguchi, K. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2003.09.008 · Cited by 79
Central Antihypertensive Effects of Orally Active Aminopeptidase A Inhibitors in Spontaneously Hypertensive Rats
Marc, Y., Gao, J., Balavoine, F., Michaud, A., Roques, B. P., & Llorens‐Cortés, C. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.190942 · Cited by 79
Improvement of albuminuria after renal denervation
Ott, C., Mahfoud, F., Schmid, A., Ditting, T., Veelken, R., Ewen, S., Ukena, C., Uder, M., Böhm, M., & Schmieder, R. E. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.03.017 · Cited by 75
Effectiveness and Safety of a Therapeutic Vaccine Against Angiotensin II Receptor Type 1 in Hypertensive Animals
Chen, X., Qiu, Z., Yang, S., Ding, D., Chen, F., Zhou, Y., Wang, M., Lin, J., Yu, X., Zhou, Z., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.201020 · Cited by 73
A digoxin-like immunoreactive substance in preeclampsia
Gusdon, J. P., Buckalew, V. M., & Hennessy, J. F. (1984) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(84)80114-3 · Cited by 72
1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia
Anandan, S., Webb, H. K., Chen, D., Wang, Y., Aavula, B. R., Cases, S., Cheng, Y., Do, Z. N., Mehra, U., Tran, V., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.042 · Cited by 72
Ethanol-mediated perivascular renal sympathetic denervation: preclinical validation of safety and efficacy in a porcine model
Fischell, T. A., Vega, F., Raju, N. R., Johnson, E. T., Kent, D. J., Ragland, R. R., Fischell, D. R., ALMANY, S. L., & Ghazarossian, V. E. (2013) · EuroIntervention · doi:10.4244/eijv9i1a20 · Cited by 71
Catheter-Based Renal Denervation for Resistant Hypertension
Papademetriou, V., Tsioufis, C. P., Sinhal, A. R., Chew, D. P., Meredith, I. T., Malaiapan, Y., Worthley, M. I., & Worthley, S. G. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03605 · Cited by 71
THE EFFECTS OF SPIRONOLACTONE AND CHLORTHALIDONE ON ARTERIAL PRESSURE
Cranston, W. I., & Juel‐Jensen, B. E. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92199-2 · Cited by 70
Inhibition of soluble epoxide hydrolase bycis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension
Neckář, J., Kopkan, L., Husková, Z., Kolář, F., Papoušek, F., Kramer, H. J., Hwang, S. H., Hammock, B. D., Imig, J. D., Malý, J., et al. (2011) · Clinical Science · doi:10.1042/cs20110622 · Cited by 70
The Effects of Aldosterone Synthase Inhibition on Aldosterone and Cortisol in Patients With Hypertension: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Study
Andersen, K. K., Hartman, D., Peppard, T., Hermann, D. J., Ess, P. J. V., Lefkowitz, M. P., & Trapani, A. J. (2012) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2012.00667.x · Cited by 70
Antidigoxin Antibodies in Eclampsia
Rc, G. (1988) · New England Journal of Medicine · doi:10.1056/nejm198802253180815 · Cited by 70
Natriuretic Peptide Receptor-C Attenuates Hypertension in Spontaneously Hypertensive Rats
Li, Y., Sarkar, O., Brochu, M., & Anand‐Srivastava, M. B. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.01772 · Cited by 69
Beneficial Effects of Long‐Term Administration of an Oral Formulation of Angiotensin‐(1–7) in Infarcted Rats
Marques, F. D., Melo, M. B., de Souza, L. E., Irigoyen, M. C., Sinisterra, R. D., Sousa, F. B. D., Savergnini, S. Q., Braga, V. B. A., Ferreira, A. J., & Santos, R. A. S. (2012) · International Journal of Hypertension · doi:10.1155/2012/795452 · Cited by 67
Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry
Vogel, B., Kirchberger, M. C., Zeier, M. G., Stoll, F., Meder, B., Saure, D., Andrassy, M., Mueller, O. J., Hardt, S. E., Schwenger, V., et al. (2013) · Clinical Research in Cardiology · doi:10.1007/s00392-013-0627-5 · Cited by 64
Opportunities for Targeting the Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas Receptor Pathway in Hypertension
Fraga-Silva, R. A., Ferreira, A. J., & Santos, R. A. S. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0324-1 · Cited by 63
Studies on Renin Antibodies
Helmer, O. M. (1958) · Circulation · doi:10.1161/01.cir.17.4.648 · Cited by 63
Aldosterone Synthase Inhibitors as Promising Treatments for Mineralocorticoid Dependent Cardiovascular and Renal Diseases
Hu, Q., Yin, L., & Hartmann, R. W. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401430e · Cited by 62
Synthesis and Biological Evaluation of Novel, Peripherally Selective Chromanyl Imidazolethione-Based Inhibitors of Dopamine β-Hydroxylase
Беляев, А. Н., Learmonth, D. A., & Soares-da-Silva, P. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051051f · Cited by 62
Pulsatile Compression of the Rostral Ventrolateral Medulla in Hypertension
Morimoto, S., Sasaki, S., Miki, S., Kawa, T., Itoh, H., Nakata, T., Takeda, K., Nakagawa, M., Naruse, S., & Maeda, T. (1997) · Hypertension · doi:10.1161/01.hyp.29.1.514 · Cited by 62
Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug
Balavoine, F., Azizi, M., Bergerot, D., Mota, N. D., Patouret, R., Roques, B. P., & Llorens‐Cortés, C. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0125-y · Cited by 59
Effects of chronic baroreceptor unloading on blood pressure in the dog
Thrasher, T. N. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00489.2004 · Cited by 59
Angiotensin 1–7: A peptide for preventing and treating metabolic syndrome
Santos, S. H. S., & Andrade, J. M. O. (2014) · Peptides · doi:10.1016/j.peptides.2014.07.002 · Cited by 58
Noninvasive Renal Sympathetic Denervation by Extracorporeal High-Intensity Focused Ultrasound in a Pre-Clinical Canine Model
Wang, Q., Guo, R., Rong, S., Yang, G., Zhu, Q., Jiang, Y., Deng, C., Liu, D., Zhou, Q., Wu, Q., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.050 · Cited by 58
Investigation of aldosterone-synthase inhibition in rats
Ménard, J., Gonzalez, M.-F., Guyene, T.-T., & Bissery, A. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000226205.65442.f2 · Cited by 57
Novel Pyridyl- or Isoquinolinyl-Substituted Indolines and Indoles as Potent and Selective Aldosterone Synthase Inhibitors
Yin, L., Hu, Q., Emmerich, J., Lo, M. M. ‐., Metzger, E., Ali, A., & Hartmann, R. W. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500140c · Cited by 57
Deactivation of carotid body chemoreceptors by hyperoxia decreases blood pressure in hypertensive patients
Siński, M., Lewandowski, J., Przybylski, J., Zalewski, P., Symonides, B., Abramczyk, P., & Gaciong, Z. A. (2014) · Hypertension Research · doi:10.1038/hr.2014.91 · Cited by 56
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy
Schumacher, C., Steele, R. E., & Brunner, H. R. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328363570c · Cited by 56
Volume sensitive hypertension and the digoxin-like factor reversal by a fab directed against digoxin in DOCA-salt hypertensive rats
Krep, H., Price, D. A., Soszynski, P. A., Tao, Q., Graves, S. W., & Hollenberg, N. K. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)00181-n · Cited by 54
Aldosterone synthase inhibitors in hypertension: current status and future possibilities
Hargovan, M., & Ferro, A. (2014) · JRSM Cardiovascular Disease · doi:10.1177/2048004014522440 · Cited by 54
Evaluation of two carrier protein–angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man
Downham, M. R., Auton, T. R., Rosul, A., Sharp, H. L., Sjöström, L., Rushton, A. B., Richards, J. P., Mant, T., Gardiner, S. M., Bennett, T. M., et al. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01926.x · Cited by 53
Decrease in Blood Pressure and Regression of Cardiovascular Complications by Angiotensin II Vaccine in Mice
Nakagami, F., Koriyama, H., Nakagami, H., Osako, M. K., Shimamura, M., Kyutoku, M., Miyake, T., Katsuya, T., Rakugi, H., & Morishita, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060493 · Cited by 53
Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension
Faul, J. L., Schoors, D. F., Brouwers, S., Scott, B., Jerrentrup, A., Galvin, J., Luitjens, S. F., & Dolan, E. (2014) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2013.10.069 · Cited by 52
Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study
Williams, B., Cockcroft, J. R., Kario, K., Zappe, D., Cardenas, P., Hester, A., Brunel, P., & Zhang, J. Y. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004254 · Cited by 52
Why are mineralocorticoid receptor antagonists cardioprotective?
Chai, W., & Danser, A. H. J. (2006) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-006-0107-9 · Cited by 51
Arteriovenous Anastomosis
Burchell, A. E., Lobo, M. D., Sulke, N., Sobotka, P. A., & Paton, J. F. R. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.02925 · Cited by 51
Neprilysin Inhibition — A Novel Therapy for Heart Failure
Jessup, M. L. (2014) · New England Journal of Medicine · doi:10.1056/nejme1409898 · Cited by 48
The Novel Mas agonist, CGEN-856S, Attenuates Isoproterenol-Induced Cardiac Remodeling and Myocardial Infarction Injury in Rats
Savergnini, S. Q., Ianzer, D. A., Carvalho, M. B. L., Ferreira, A. J., Silva, G. A. B., Marques, F. D., Peluso, A. A., Beiman, M., Cojocaru, G., Cohen, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057757 · Cited by 46
Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure
Dickstein, K., de Voogd, H. J., Mirić, M., Willenbrock, R., Mitrović, V. L., Pacher, R., & Koopman, P. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.03.074 · Cited by 43
Proper Patient Selection Yields Significant and Sustained Reduction in Systolic Blood Pressure Following Renal Artery Stenting in Patients With Uncontrolled Hypertension: Long‐Term Results From the HERCULES Trial
Chrysant, G. S., Bates, M. C., Sullivan, T. M., Bachinsky, W., Popma, J. J., Peng, L., Omran, H. L., Jaff, M. R., & the HERCULES Investigators (2014) · Journal of Clinical Hypertension · doi:10.1111/jch.12341 · Cited by 43
Renal Artery Revascularization
Bavry, A. A., Kapadia, S. R., Bhatt, D. L., & Kumbhani, D. J. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.4332 · Cited by 43
Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial
Parvanova, A. I., van der Meer, I. M., Iliev, I. P., Perna, A., Gaspari, F., Trevisan, R., Bossi, A. C., Remuzzi, G., Benigni, A., & Ruggenenti, P. L. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70029-9 · Cited by 43
Renal Denervation for Resistant Hypertension
Oriol Rodríguez-leor, C., Bonet, J., & Bayés‐Genís, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1405677 · Cited by 42
Impact of the AT2 Receptor Agonist C21 on Blood Pressure and Beyond
Foulquier, S., Steckelings, U. M., & Unger, T. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0291-6 · Cited by 41
Disproportional Decrease in Office Blood Pressure Compared With 24-Hour Ambulatory Blood Pressure With Antihypertensive Treatment
Schmieder, R. E., Schmidt, S. T., Riemer, T., Dechend, R., Hagedorn, I., Senges, J., Messerli, F. H., & Zeymer, U. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.03140 · Cited by 41
Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA–salt-induced hypertension in rats
Singh, Y. P., Singh, K., & Sharma, P. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1489-2 · Cited by 40
Blood pressure response to renal artery stenting in 901 patients from five prospective multicenter FDA‐approved trials
Weinberg, I., Keyes, M. J., Giri, J., Rogers, K. R., Olin, J. W., White, C. J., & Jaff, M. R. (2014) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.25263 · Cited by 38
Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism
Amar, L., Azizi, M., Ménard, J., Peyrard, S., & Plouin, P. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835d6d49 · Cited by 38
HORMONAL AND ELECTROLYTE RESPONSES TO THE ALDOSTERONE SYNTHASE INHIBITOR LCI699 IN SODIUM DEPLETED HEALTHY SUBJECTS
Ménard, J., Watson, C. E., Rebello, S. S., Zhang, Y. M., & Dole, W. P. (2010) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(10)60584-0 · Cited by 38
Temporary Reduction of Blood Pressure and Sympathetic Nerve Activity in Hypertensive Patients After Microvascular Decompression
Frank, H., Heusser, K., Geiger, H., Fahlbusch, R., Naraghi, R., & Schobel, H. P. (2008) · Stroke · doi:10.1161/strokeaha.108.518670 · Cited by 38
Microvascular Decompression for Hypertension
Yamamoto, I., Yamada, S., & Sato, O. (1991) · Neurologia medico-chirurgica · doi:10.2176/nmc.31.1 · Cited by 37
Aminopeptidase A inhibitors as centrally acting antihypertensive agents
Bodineau, L., Frugière, A., Marc, Y., Claperon, C., & Llorens‐Cortés, C. (2008) · Heart Failure Reviews · doi:10.1007/s10741-007-9077-3 · Cited by 37
Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes
Tikkanen, I. T., Tikkanen, T., Cao, Z., Allen, T. J., Davis, B. J., Lassila, M., CASLEY, D. J., Johnston, C. I., Burrell, L. M., & Cooper, M. E. (2002) · Journal of Hypertension · doi:10.1097/00004872-200204000-00029 · Cited by 36
Success and failure of vaccines against renin–angiotensin system components
Brown, M. J. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.156 · Cited by 35
Etamicastat, a Novel Dopamine β-Hydroxylase Inhibitor: Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Hypertension
Almeida, L., Nunes, T., Costa, R., Rocha, J., Vaz‐da‐Silva, M., & Soares-da-Silva, P. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.10.012 · Cited by 32
Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?
Ménard, J., & Pascoe, L. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000226183.98439.b3 · Cited by 31
Long-Term Results After Microvascular Decompression in Essential Hypertension
Frank, H., Schobel, H.-P., Heusser, K., Geiger, H., Fahlbusch, R., & Naraghi, R. (2001) · Stroke · doi:10.1161/hs1201.099799 · Cited by 30
Digoxin Immune Fab Treatment for Severe Preeclampsia
Adair, C. D., Buckalew, V. M., Graves, S. W., Lam, G. K., Johnson, D., Saade, G. R., Lewis, D. F., Robinson, C., Danoff, T. M., Chauhan, N., et al. (2010) · American Journal of Perinatology · doi:10.1055/s-0030-1249762 · Cited by 30
The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans
Seed, A., Kuc, R. E., Maguire, J. J., Hillier, C., Johnston, F., Essers, H., de Voogd, H. J., McMurray, J. J. V., & Davenport, A. P. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.03.022 · Cited by 30
In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH2) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator
Edelson, J. D., Makhlina, M., Silvester, K. R., Vengurlekar, S. S., Chen, X., Zhang, J., Koziol‐White, C. J., Cooper, P. R., Hallam, T. J., Hay, D. W. P., et al. (2012) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2012.11.001 · Cited by 29
Digoxin antibody fragment, antigen binding (Fab), treatment of preeclampsia in women with endogenous digitalis-like factor: a secondary analysis of the DEEP Trial
Lam, G. K., Hopoate-Sitake, M., Adair, C. D., Buckalew, V. M., Johnson, D., Lewis, D. F., Robinson, C., Saade, G. R., & Graves, S. W. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.04.010 · Cited by 29
From SYMPLICITY HTN-3 to the Renal Denervation Global Registry: where do we stand and where should we go?
Pathak, A., Ewen, S., Fajadet, J. C., Honton, B., Mahfoud, F., Marco, J., Schlaich, M. P., Schmieder, R. E., Tsioufis, K. P., Ukena, C., et al. (2014) · EuroIntervention · doi:10.4244/eijv10i1a4 · Cited by 29
Immediate Effects of Bilateral Carotid Body Resection on Total Respiratory Resistance and Compliance in Humans
Winter, B., & Whipp, B. J. (2004) · Advances in experimental medicine and biology · doi:10.1007/0-387-27023-x_3 · Cited by 27
Aldosterone, Hypertension, and Cardiovascular Disease
Ruilope, L. M. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.111211 · Cited by 26
Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive rat
Igreja, B., Pires, N. M., Bonifácio, M. J., Loureiro, A. I., Fernandes‐Lopes, C., Wright, L. C., & Soares-da-Silva, P. (2014) · Hypertension Research · doi:10.1038/hr.2014.143 · Cited by 25
Inhibition of Both Neutral Endopeptidase and Endothelin-Converting Enzyme by SLV306 Reduces Proteinuria and Urinary Albumin Excretion in Diabetic Rats
ne-Reinke, C. T., Simon, K., Richter, C.-M., Godes, M., Neumayer, H., hlen, D. T., & Hocher, B. (2004) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000166208.12297.8d · Cited by 25
Aldosterone synthase inhibitors: pharmacological and clinical aspects.
Jansen, P. M., van den Meiracker, A. H., & Danser, A. J. (2009) · PubMed · Cited by 22
Immunologic approaches to blockade of the renin-angiotensin system: A review
Michel, J., Guettier, C., Reade, R., Sayah, S., Corvol, P. L., & Ménard, J. (1989) · American Heart Journal · doi:10.1016/0002-8703(89)90767-9 · Cited by 22
Hypertension Vaccine may be a boon to millions in developing world
Bairwa, M. L., Pilania, M., Gupta, V., & Yadav, K. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.27520 · Cited by 19
DigiFab Interacts With Endogenous Cardiotonic Steroids and Reverses Preeclampsia-Induced Na/K-ATPase Inhibition
Ishkaraeva, V. V., Fedorova, O. V., Solodovnikova, N. G., Frolova, E. V., Bzhelyansky, A., Emelyanov, I. V., Adair, D. C., Zazerskaya, I. E., & Bagrov, A. Y. (2012) · Reproductive Sciences · doi:10.1177/1933719112447124 · Cited by 19
Construction, expression and immunogenicity of a novel anti-hypertension angiotensin II vaccine based on hepatitis A virus-like particle
Ou, X., Guo, L., Wu, J., Mi, K., Yin, N., Zhang, G., Li, H., & Sun, M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23940 · Cited by 18
Exploring the Role of Antithrombin Replacement for the Treatment of Preeclampsia: A Prospective Randomized Evaluation of the Safety and Efficacy of Recombinant Antithrombin in Very Preterm Preeclampsia ( PRESERVE ‐1)
Paidas, M. J., Sibai, B. M., Triche, E. W., Frieling, J. T. M., Lowry, S., & The PRESERVE‐1 Study Group (2013) · American Journal of Reproductive Immunology · doi:10.1111/aji.12091 · Cited by 17
Angiotensin‐(1‐7)/Angiotensin‐Converting Enzyme 2/Mas Receptor Axis and Related Mechanisms
Ferreira, A. J., Santos, R. A. S., & Raizada, M. K. (2012) · International Journal of Hypertension · doi:10.1155/2012/690785 · Cited by 15

Research works printed but not linked: 7

Van der Meer I Benigni A Parvanova A Iliev I Sharma S Cruz J et al.. Pressure control by combined ECE/NEP inhibitor on top of losartan: a randomized cross-over placebo-controlled clinical trial in patients with type 2 diabetes and albuminuria. Twelfth International Conference on Endothelin; 2011. p. 50.
Wong K, Zhang L-N, Vincelette J, Chen D, Tran V, Mehra U, Gless R, Anandan S-K, Webb HK, MacIntyre U, Wang Y-X. A novel inhibitor of soluble epoxide hydrolase, AR9281, improves glucose homeostasis in diet-induced obese mice. American Diabetes Society 69th Scientific Sessions. New Orleans. Diabetes. 2009;58:A436 (1698-A).
10.1056/NEJMc1402687 · DOI
Walton T, Hardin S, Rothman M, Whitbourn R. Renal artery denervation with a new simultaneous multielectrode catheter for treatment of resistant hypertension: Six month results from the symplicity spyral first-in-man study. EuroPCR. 2014;Euro14A–OP209.
Verheye S, Ormiston J, Kuck KH, Bergmann M, Sievert H, Torsello G, Dens JAY, Grube E, Colombo A, Vogel B, Voskuil M, Daemen J. Safety and effectiveness of catheter-based renal sympathetic denervation for the treatment of resistant hypertension: 12-month results of the rapid study. EuroPCR. 2014:14A–OP208.
Zeller T, Andersson B, Bohm M, Kuck KH, Sievert H, Graf T, Kahlert P, Daemen J. The paradise renal denervation system: Initial clinical results from the achieve study. EuroPCR. 2014:14A–OP205.
Shetty S, Blessing E, Roenschein U, Scheinert D, Diehm N, Jonas M. Renal denervation using the novel therapeutic intra-vascular ultrasound (tivus) catheter system - preliminary report of first-in-man safety and performance study. EuroPCR. 2014:14A–OP206.

Sorted by citations

Hypertension.
Oparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., Grassi, G., Jordan, J., Poulter, N. R., Rodgers, A., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.14 · Cited by 1,167
Self-citation
Adherence in Hypertension: A Review of Prevalence, Risk Factors, Impact, and Management
Burnier, M., & Egan, B. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313220 · Cited by 878
Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19
Kreutz, R. H., Algharably, E. A. E., Azizi, M., Dobrowolski, P., Guzik, T. J., Januszewicz, A., Persu, A., Prejbisz, A., Riemer, T., Wang, J., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa097 · Cited by 366
Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
Coulson, L. B., Danser, A. H. J., Poglitsch, M., Touyz, R. M., Burnett, J. C. J., Llorens‐Cortés, C., Ehlers, M. R., & Sturrock, E. D. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017129 · Cited by 346
COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study
Huang, S., Wang, J., Liu, F., Liu, J., Cao, G., Yang, C., Liu, W. Y., Tu, C., Zhu, M., & Xiong, B. (2020) · Hypertension Research · doi:10.1038/s41440-020-0485-2 · Cited by 227

See all 277

Authors: Oparil, S., & Schmieder, R. E.
Affiliations: University of Alabama at Birmingham Hospital (US)
ORCID: Oparil, Suzanne
Schmieder, Roland E.
Venue: Circulation Research
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2015-03-13
Volume: 116
Issue: 6
Pages: 1074-1095
ISSN: 0009-7330 (ISSN-L)
1524-4571
DOI: 10.1161/circresaha.116.303603
OpenAlex: W2138173257
Cited by: 276
References: 213
Citations by year: 2026: 10 · 2025: 14 · 2024: 20 · 2023: 26 · 2022: 23 · 2021: 27 · 2020: 30 · 2019: 33 · 2018: 26 · 2017: 29 · 2016: 24 · 2015: 14
FWCI: 22.79
Type: journal article
Language: en
Open access: closed
Locations: Circulation Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords: hypertension, antihypertensive drugs, treatment-resistant hypertension, vasopeptidase inhibitors, aldosterone synthase inhibitors, soluble epoxide hydrolase inhibitors, mineralocorticoid receptor antagonists, dopamine beta-hydroxylase inhibitor, Na+/H+ exchanger 3, baroreflex activation therapy, arteriovenous fistula, cardiovascular disease prevention, uncontrolled hypertension
MeSH terms: Mineralocorticoid Receptor Antagonists, Animals, Antihypertensive Agents, Arteriovenous Shunt, Surgical, Carotid Body, Clinical Trials as Topic, Electric Stimulation Therapy, Enzyme Inhibitors, Female, Humans, Hypertension, Ion Channels, Kidney, Kidney Tubules, Pre-Eclampsia, Pregnancy, Pressoreceptors, Receptors, Cell Surface, Renal Artery, Renin-Angiotensin System, Sympathectomy, Sympathetic Nervous System, Drug Design, Multicenter Studies as Topic, Drugs, Investigational, Stents, Comorbidity, Randomized Controlled Trials as Topic, Baroreflex, Oxidative Stress, Decompression, Surgical, Models, Animal, Therapies, Investigational, High-Intensity Focused Ultrasound Ablation, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

New Approaches in the Treatment of Hypertension

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks